The MetaNeb® System
Three therapies. One device.
An effective and efficient solution.
Three therapies. One device. An effective and efficient solution.

The MetaNeb® System is designed to mobilize retained secretions, lung expansion therapy, and to deliver medicated aerosol for the treatment and prevention of pulmonary atelectasis. It also has the ability to provide supplemental oxygen when used with compressed oxygen.

The MetaTherapy® treatment maximizes efficiency for patients and clinicians by combining three treatments into a single integrated therapy by The MetaNeb System. It may reduce therapy time to just 10 minutes,* and eliminate the need to switch devices.

MetaTherapy treatment delivered through a single unit:

- Simple to “connect and go” design.
- Single patient use (SPU) circuit includes mouthpiece, nebulizer, mask/trach adapter, and in-line ventilator setup.
- Quickly switch between therapy cycles.
- Easily adjustable flow, pressure and percussive rate.
POST-OPERATIVE PATIENTS ARE AT RISK OF PULMONARY COMPLICATIONS.

UP TO 40% OF POST-SURGICAL PATIENTS EXPERIENCE PPC.¹

Developing a pulmonary complication can increase hospital length-of-stay (LOS), ICU and hospital readmissions, mortality and healthcare costs.¹

EVIDENCE SHOWS THAT LUNG EXPANSION TECHNIQUES CAN HELP.

Guidelines recommend the use of lung expansion therapies with evidence showing 50% reduction of PPCs.¹² Preventing PPCs can reduce associated cost per patient by up to 92%.¹
Providing effective pulmonary therapies for critical care patients leading to improved clinical outcomes.

- Flexible 3-1 therapy enables seamless delivery to meet patient needs:
  - Aerosol Delivery
  - Secretion clearance
  - Lung expansion
- Mechanically driven requiring minimal patient effort for effective therapy.
- Caregivers’ consistent engagement and administration ensures compliance of the therapy delivery.

50% REDUCTION IN PULMONARY COMPLICATIONS.¹

UP TO 1 DAY REDUCTION IN ICU LENGTH OF STAY WITH LUNG EXPANSION THERAPY.²

UP TO 2 DAY REDUCTION IN HOSPITAL LENGTH OF STAY WITH LUNG EXPANSION THERAPY.²
The MetaNeb® System 10-Minute Therapy Cycle

ALTERNATING CYCLES OF CPEP AND CHFO COMBINED WITH AEROSOL DELIVERY HELP MAXIMIZE THERAPY EFFECTIVENESS.

Introduces CHFO therapy immediately after lungs have been expanded through CPEP.

Aerosol delivered in both lung expansion and secretion clearance.

*Therapy times may differ depending on patient ordered therapies.
CHFO = Continuous High Frequency Oscillation
CPEP = Continuous Positive Expiratory Pressure
What does a MetaNeb® System patient look like?

Patient Populations Benefiting from MetaNeb® Treatments:
Post-operative, trauma, spinal cord injuries, neuromuscular, chronic pulmonary conditions, pneumonia, emergency department and bariatric.

Assessing a Patient for MetaNeb Therapy

**EXCESSIVE SECRETION PRODUCTION**
- Sputum production high
- Evidence of retained secretions in the presence of an artificial airway

**INEFFECTIVE COUGH**
- Inability to clear secretions
- Inability to take a deep breath (e.g., from incisional pain, muscle weakness)

**INADEQUATE LUNG EXPANSION**
- Abnormal chest x-ray
- Presence of atelectasis – clinically significant
Three therapies. One device. An effective and efficient solution.
Hill-Rom is a leading global medical technology company with more than 10,000 employees worldwide. We partner with health care providers in more than 100 countries, across all care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: Advancing Mobility, Wound Care and Prevention, Patient Monitoring and Diagnostics, Surgical Safety and Efficiency and Respiratory Health. Hill-Rom’s people, products and programs work towards one mission: Every day, around the world, we enhance outcomes for patients and their caregivers.

References